Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Tecentriq Now FDA Approved for Treatment of Alveolar Soft-Part Sarcoma

JHOP - February 2023 Vol 13, No 1 - FDA Oncology Update

On December 9, 2022, the FDA approved atezolizumab (Tecentriq; Genentech), a PD-L1 inhibitor, for patients aged ≥2 years with unresectable or metastatic alveolar soft-part sarcoma (ASPS), a type of soft-tissue sarcoma. The FDA granted atezolizumab breakthrough therapy and orphan drug designations for this indication.

Atezolizumab was previously approved for many indications.

The approval of atezolizumab for ASPS was based on results of Study ML39345, an open-label, single-arm clinical trial of adult and pediatric patients with unresectable or metastatic ASPS. Eligible patients had histologically or cytologically confirmed unresectable ASPS. Patients were excluded if they had primary central nervous system (CNS) malignancy or symptomatic CNS metastases, liver disease, or a history of idiopathic pulmonary fibrosis, pneumonitis, organizing pneumonia, or active pneumonitis on imaging.

Of the 49 patients in the study, 47 were adults and 2 were pediatric patients (aged ≥12 years), with a median age of 31 years (range, 12-70 years). Adult patients received atezolizumab 1200 mg intravenously and pediatric patients received 15 mg/kg (up to a maximum of 1200 mg) intravenously once every 21 days, until disease progression or unacceptable adverse events.

The overall response rate was 24% (95% confidence interval, 13-39). Among the 12 patients who had an objective response, 67% had a response lasting ≥6 months, and 42% had a response lasting ≥12 months.

The most common (≥20%) adverse reactions were musculoskeletal pain (67%); fatigue (55%); rash (47%); cough (45%); nausea, headache, and hypertension (43% each); vomiting (37%); constipation and dyspnea (33% each); dizziness and hemorrhage (29% each); insomnia and diarrhea (27% each); pyrexia, anxiety, abdominal pain, and hypothyroidism (25% each); and decreased appetite and arrhythmia (22% each).

Related Items
Gavreto Received Regular FDA Approval for Patients With Non–Small Cell Lung Cancer and RET Gene Fusion
Online First published on September 8, 2023 in FDA Oncology Update
FDA Accelerated the Approval of Akeega, First and Only Dual-Action Tablet for Metastatic Prostate Cancer With BRCA Mutation
Online First published on September 8, 2023 in FDA Oncology Update
FDA Granted Accelerated Approval to Elrexfio, a Bispecific BCMA-Directed CD3 T-Cell Engager, for Relapsed or Refractory MM
Online First published on September 8, 2023 in FDA Oncology Update
Hepzato Kit FDA Approved as a Liver-Directed Treatment for Uveal Melanoma With Hepatic Metastases
Online First published on September 8, 2023 in FDA Oncology Update
FDA Accelerated the Approval of Talvey, First Bispecific GPRC5D-Directed CD3 T-Cell Engager, for Relapsed or Refractory MM
Online First published on September 8, 2023 in FDA Oncology Update
FDA Accelerated the Approval of Columvi for Selected Relapsed or Refractory Large B-Cell Lymphomas
JHOP - August 2023 Vol 13, No 4 published on August 17, 2023 in FDA Oncology Update
Lonsurf Received a New Indication, in Combination With Bevacizumab, for Previously Treated Metastatic Colorectal Cancer
JHOP - August 2023 Vol 13, No 4 published on August 7, 2023 in FDA Oncology Update
Jemperli Plus Chemotherapy Now FDA Approved for Front-Line Treatment of dMMR or MSI-H Endometrial Cancer
JHOP - August 2023 Vol 13, No 4 published on August 4, 2023 in FDA Oncology Update
Vanflyta Now Approved for Newly Diagnosed FLT3-ITD–Positive AML
JHOP - August 2023 Vol 13, No 4 published on July 28, 2023 in FDA Oncology Update
Talzenna Received a New Indication, With Enzalutamide, for Metastatic Castration-Resistant Prostate Cancer With HRR Gene Mutation
JHOP - August 2023 Vol 13, No 4 published on June 30, 2023 in FDA Oncology Update
© Amplity Health. All rights reserved.